Endometrial Cancer Incidence in Endometriosis and Adenomyosis

Simple Summary Previous research shows that women with endometriosis and adenomyosis have an increased ovarian cancer risk. However, it is unclear whether these women have an increased risk of developing uterine cancer. This information is of key importance to women with endometriosis or adenomyosis. Therefore, this study aims to assess the uterine cancer risk in women with endometriosis or adenomyosis in a large population. Abstract Women with histologically proven endometriosis/adenomyosis have an increased risk of ovarian cancer. Small studies show conflicting results on the endometrial cancer risk in women with endometriosis/adenomyosis. Therefore, we assessed the incidence of endometrial cancer in women with histologically proven endometriosis or adenomyosis. We performed a population-based retrospective cohort study of 129,862 women with histologically proven endometriosis/adenomyosis, matched with 132,700 women with a nevus selected from the Dutch pathology registry between 1990 and 2015. Histology results for endometrial cancer were retrieved. Crude and age-adjusted odds ratios for endometrial cancer were estimated. In the endometriosis/adenomyosis group, 1827 (1.4%) women had a histological report on endometrial cancer, and in the nevus group, 771 (0.6%) women. The age-adjusted OR for endometrial cancer was 2.58 (95%CI 2.37–2.81). After excluding the first year of follow-up, the age-adjusted OR was 0.76 (95%CI 0.63–0.92), indicating that endometrial cancer is most often found at time of histological diagnosis of endometriosis/adenomyosis. In around 20% of the endometrial cancer cases, the endometrial cancer was not recognized until after hysterectomy. Of these women, 35% had no prior (micro)curettage or biopsy. This study shows an increased incidence of endometrial cancer in women with histologically proven endometriosis and adenomyosis.

[1]  M. van der Aa,et al.  OP017/#81 Endometrial cancer prognosis in women with endometriosis and adenomyosis. A retrospective nationwide cohort study of 40,847 women , 2021, Oral Featured Posters.

[2]  L. Insabato,et al.  Impact of adenomyosis on the prognosis of patients with endometrial cancer , 2021, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[3]  K. Zondervan,et al.  Endometriosis and cancer: a systematic review and meta-analysis. , 2020, Human reproduction.

[4]  F. Petraglia,et al.  Immunological changes associated with adenomyosis: a systematic review. , 2020, Human reproduction update.

[5]  L. Insabato,et al.  Prevalence of adenomyosis in endometrial cancer patients: a systematic review and meta-analysis , 2020, Archives of Gynecology and Obstetrics.

[6]  S. Kyo,et al.  Cancer‐associated mutations in normal human endometrium: Surprise or expected? , 2020, Cancer science.

[7]  A. Ignatov,et al.  Endocrine Risk Factors of Endometrial Cancer: Polycystic Ovary Syndrome, Oral Contraceptives, Infertility, Tamoxifen , 2020, Cancers.

[8]  D. Boll,et al.  Incidence and predictors of peritoneal metastases of gynecological origin: a population-based study in the Netherlands , 2020, Journal of gynecologic oncology.

[9]  Mingzhi Zhao,et al.  Association of benign gynaecological diseases and risk of endometrial and ovarian cancers , 2020, Journal of Cancer.

[10]  T. Van den Bosch,et al.  Diagnosing adenomyosis: an integrated clinical and imaging approach. , 2020, Human reproduction update.

[11]  D. Kalaitzopoulos,et al.  Association between endometriosis and gynecological cancers: a critical review of the literature , 2020, Archives of Gynecology and Obstetrics.

[12]  R. Bekkers,et al.  Incidence of endometrioid and clear-cell ovarian cancer in histological proven endometriosis. The ENOCA population-based cohort study. , 2020, American journal of obstetrics and gynecology.

[13]  S. Reed,et al.  ADENOMYOSIS INCIDENCE, PREVALENCE AND TREATMENT: UNITED STATES POPULATION-BASED STUDY 2006-2015. , 2020, American journal of obstetrics and gynecology.

[14]  E. Kontomanolis,et al.  The Role of ARID1A in Endometrial Cancer and the Molecular Pathways Associated With Pathogenesis and Cancer Progression , 2019, In Vivo.

[15]  F. Amant,et al.  Cancer of the corpus uteri , 2018, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[16]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[17]  F. Batteux,et al.  Immunology of endometriosis. , 2004, Best practice & research. Clinical obstetrics & gynaecology.

[18]  M. Gissler,et al.  Risk of Gynecologic Cancer According to the Type of Endometriosis. , 2018, Obstetrics and gynecology.

[19]  S. Gordts,et al.  Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis. , 2018, Fertility and sterility.

[20]  L. Saraswat,et al.  Impact of endometriosis on risk of further gynaecological surgery and cancer: a national cohort study , 2018, BJOG : an international journal of obstetrics and gynaecology.

[21]  F. Petraglia,et al.  Pathogenesis of adenomyosis: an update on molecular mechanisms. , 2017, Reproductive biomedicine online.

[22]  Wei Zheng,et al.  Malignant changes in adenomyosis in patients with endometrial adenocarcinoma , 2017, Medicine.

[23]  L. Postovit,et al.  Epithelial-to-Mesenchymal Transition in the Female Reproductive Tract: From Normal Functioning to Disease Pathology , 2017, Front. Oncol..

[24]  L. Wood,et al.  Cancer‐Associated Mutations in Endometriosis without Cancer , 2017, The New England journal of medicine.

[25]  A. Jensen,et al.  Endometriosis and risks for ovarian, endometrial and breast cancers: A nationwide cohort study. , 2016, Gynecologic oncology.

[26]  Horng‐Jyh Tsai,et al.  The Risks for Ovarian, Endometrial, Breast, Colorectal, and Other Cancers in Women With Newly Diagnosed Endometriosis or Adenomyosis: A Population-Based Study , 2015, International Journal of Gynecologic Cancer.

[27]  A. Prentice,et al.  ESHRE guideline: management of women with endometriosis. , 2014, Human reproduction.

[28]  A. Qureshi,et al.  Pigmentary traits, family history of melanoma and the risk of endometriosis: a cohort study of US women. , 2014, International journal of epidemiology.

[29]  P. Schembri-Wismayer,et al.  Molecular links between endometriosis and cancer , 2012, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[30]  M. Pike,et al.  Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.

[31]  A. Mueck,et al.  Hormonal contraception and risk of endometrial cancer: a systematic review. , 2010, Endocrine-related cancer.

[32]  R. Stone,et al.  Factors associated with Type I and Type II endometrial cancer , 2010, Cancer Causes & Control.

[33]  L. Hummelshoj,et al.  Creating Solutions in Endometriosis: Global Collaboration through the World Endometriosis Research Foundation: , 2010 .

[34]  L. Hummelshoj,et al.  Creating Solutions in Endometriosis: Global Collaboration through the World Endometriosis Research Foundation , 2010 .

[35]  F. Clavel-Chapelon,et al.  Endometriosis risk in relation to naevi, freckles and skin sensitivity to sun exposure: the French E3N cohort. , 2009, International journal of epidemiology.

[36]  P. Hevezi,et al.  Molecular characterization of human adenomyosis. , 2006, Molecular human reproduction.

[37]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[38]  P. Clement,et al.  Endometrioid Carcinoma of the Uterine Corpus: A Review of Its Pathology With Emphasis on Recent Advances and Problematic Aspects , 2002, Advances in anatomic pathology.

[39]  A. Prentice Epidemiology of endometriosis. , 1993, BMJ.

[40]  Michael Karin,et al.  NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.